Search Results
Jun 05, 2026, 12:00 ET SUBARU EARNS NINE SPOTS ON IIHS AND CONSUMER REPORTS 2026 TEEN DRIVER VEHICLE RECOMMENDATION LIST
safer and healthier world. For 80 years, CR has provided evidence-based product testing and ratings, rigorous research, hard-hitting investigative journalism, public education and steadfast policy action on behalf of consumers' interests. For more information from CR, go to
More news about: Subaru of America, Inc.
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
treatment with covalent BTK inhibitors. As of June 5, 2025, clinical trial data showed an objective response rate (ORR) of 63.9%, a complete response rate (CR) of 23%, and a median duration of response (mDOR) of 16.5 months. All enrolled patients had previously received at least a covalent BTK inhibitor; more
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 21:52 ET 2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma
6.1% observed in the control group. Moreover, some patients in the treatment group converted from long-term partial response (PR) to complete response (CR), demonstrating excellent efficacy.
More news about: Juncell Therapeutics
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
was 58.1% vs. 45.2%, CR rate was 39.5% vs. 26.7%, median duration of response (DOR) was 9.2 months vs. 7.7 months, and median DoCR was 16.8 months vs. 12.3 months for ZYNLONTA plus rituximab compared to R-GemOx, respectively. Of patients achieving CR, 48.5% vs. 16.7% remained in CR at 24 months in favor
More news about: ADC Therapeutics SA
Jun 03, 2026, 08:00 ET Kelley Blue Book Names the 12 Best Family Cars of 2026
alphabetical order by brand, are Kelley Blue Book's 2026 choices for the 12 Best Family Cars:Best 2-Row SUVs for Families 2026 Honda CR-V2026 Hyundai Ioniq 52026 Toyota RAV4Best 3-Row SUVs for Families 2026 Chevrolet Tahoe2026 Ford Expedition2026
More news about: Kelley Blue Book
Jun 03, 2026, 07:05 ET Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
performance.Based on internal report 43463CR757, Memorandum — ProGrip™ advanced self-gripping polypropylene mesh — advanced robotic mesh.Based on internal report 43463CR506, Design verification report. Based on internal report 43463CR740, Design validation lab of ProGrip™ advanced
More news about: Medtronic plc
Jun 02, 2026, 15:24 ET InventHelp Inventor Develops Personal Service Droid (CTK-5207)
personal service droid to help people like me and others who are deaf or mute," said an inventor from Omaha, Nebraska. As a result, they developed the CR75 DROID REMOTE ACTIVATED, designed to provide a convenient sign language interpreter, alerts to enhance safety, and a friendly companion.
More news about: InventHelp
Jun 02, 2026, 10:23 ET Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
cytogenetics76% received more than two prior therapies76% received prior venetoclaxA modified objective response rate (defined as CR + Stable Disease with neutrophil count improvement) was achieved in:50% (6/12) of patients with high PI3K-gamma expression vs.
More news about: Stelexis BioSciences, Inc.
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
ongoing response greater than three years.48% of efficacy-evaluable patients (10 of 21) achieved clinical benefit, defined as complete response (CR), partial response (PR), or durable stable disease lasting at least six months:Median progression-free survival (mPFS) of 20.5 months
More news about: Citius Oncology, Inc.
May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
(RP2D), ORR surged to 66.7%, with a disease control rate (DCR) nearing 90%.Durability was profound: One patient achieved a complete response (CR) lasting 24 months.Safety was manageable: No immune effector cell-associated neurotoxicity syndrome (ICANS) or off-tumor toxicity was observed,
More news about: Oricell Therapeutics Holdings Limited
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
months, and 9 months, as well as at any assessed timepoint— a marked step up from the lower-dose 2×109 PFU cohort, which achieved a 66.7% CR rate at any timepoint (with timepoint-specific CRRs of 55.6% at 3 months and 75.0% at 6 months). The 12-month CRR for the 1×1010 PFU cohort
More news about: ImmVira Group
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
and Keytruda (Pembrolizumab) as. In addition to the 75% response rate in the first-line (1L) patient group (including 1 CR and 8 PR), which drew attention upon abstract release on May 22, the presentation also disclosed progression-free survival (mPFS) and overall survival
More news about: TiumBio
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
More news about: Kelun-Biotech
May 29, 2026, 22:30 ET Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform
capabilities, and secured several marquee mandates across corporate, institutional and government segments.Consolidated Key Financials (Rs. Cr.):
More news about: Mach Travel Solutions Limited
May 29, 2026, 10:00 ET Hankook Tire Receives Honda's '2025 Supplier Excellence Award'
has maintained a strong partnership with Honda since 2013 and currently supplies original equipment tires for Honda's key SUV lineup, including the CR-V, HR-V, Pilot, and Passport, as well as major global sedan models such as the Accord and Civic. Building on this recognition, Hankook Tire plans to further
More news about: Hankook Tire America Corp.
May 29, 2026, 09:19 ET PeproMene Bio kündigt Vortrag auf der EHA 2026 an, der günstiges Sicherheitsprofil und dauerhaftes Ansprechen mit PMB-CT01 (BAFF-R-CAR-T-Zelltherapie) bei B-Zell-Lymphomen hervorhebt, auch nach vorherigem Versagen einer CD19-CAR-T-Zelltherapie
Immuneffektorzell-assoziiertes Neurotoxizitätssyndrom (ICANS) von Grad > 1. Sieben von neun Patienten (78 %) erreichten ein vollständiges Ansprechen (CR). Zum letzten Datenschnitt waren keine Rückfälle aufgetreten und alle erzielten Ansprechen hielten weiter an, wobei das längste Ansprechen mehr als 3
More news about: PeproMene Bio, Inc.
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
significant improvement with TECVAYLI® versus standard of care, including nearly two-thirds of patients achieving a complete response or better (≥CR; 65.9% vs. 16.8%).1The overall safety profile for TECVAYLI® in the study was consistent with its known safety profile. TECVAYLI®
More news about: Johnson & Johnson
May 29, 2026, 08:15 ET PeproMene Bio annonce une présentation orale à l'EHA 2026 mettant en évidence un profil de sécurité favorable et des réponses durables avec la PMB-CT01 (thérapie CAR-T anti-BAFF-R) dans les lymphomes à cellules B, y compris après l'échec d'une thérapie CAR-T CD19 antérieure
neurotoxicité associée aux cellules effectrices immunitaires (ICANS) de grade > 1. Sept patients sur neuf (78 %) ont obtenu une réponse complète (CR). À la dernière date de clôture des données, aucune rechute n'était survenue, et toutes les réponses se poursuivaient, la réponse la plus longue dépassant
More news about: PeproMene Bio, Inc.
May 28, 2026, 13:50 ET DSC Holdings, AI Implementation Infrastructure for China's Used-Car Industry, Files for Nasdaq Listing
proposed listing on Nasdaq, underwritten by Deutsche Bank (DB), China International Capital Corporation Limited (CICC), China Renaissance Holdings Limited (CR), and Industrial and Commercial Bank of China Limited (ICBC).
More news about: DeepBlue Finance
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
(CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients
More news about: PeproMene Bio, Inc.
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
(CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients
More news about: PeproMene Bio, Inc.
May 27, 2026, 10:35 ET Crunch Franchise Brings State-of-the-Art Crunch 3.0 Gym to Phoenix, Arizona
Crunch gyms in Arizona by the end of 2026. Its parent company, CR Fitness Holdings, is a leading Crunch Fitness franchisee that currently serves over one million members. Backed by major investment firms North Castle Partners and Sixth Street, CR Fitness is on track to operate 110 locations nationwide this
More news about: Crunch Fitness
May 26, 2026, 09:02 ET Leading Crunch Franchise Group Launches Massive 2026 Personal Training "TRAINing Day" Giveaway
Street, CR Fitness is on track to operate 110 locations nationwide by the end of this year. Each new club opening will bring over 70 career opportunities to their local communities across Personal Training, Group Fitness, Sales, Operations, and more!About CR Fitness HoldingsCR Fitness
More news about: CR Fitness Holdings, LLC.
May 26, 2026, 04:41 ET 2026 India Protein Industry Report -- Skyrocketing Prices & the Next Big Disruption in a INR 30.9 Cr Market Growing at 17.7% CAGR
provides segment-level intelligence across four distinct markets: Ingredients (INR 9,992.8 Cr), Supplements (INR 6,353 Cr), High Protein FMCG (INR 14,015.5 Cr), and Emerging & Niche Proteins (INR 623.9 Cr) — with 10-year forecasts, competitive landscape analysis, consumer trend insights, and strategic
More news about: Market Decipher
May 26, 2026, 00:00 ET SK chemicals' sieben Kunststoffmaterialien als kompatibel mit europäischen Recyclingprozessen bestätigt
allgemeinen SKYPET-Familie. Die fünf ECOTRIA-CLARO-Produkte – ECOTRIA CLARO 100, ECOTRIA CLARO 200, ECOTRIA CLARO 300, ECOTRIA CLARO 100 CR50N und ECOTRIA CLARO 200 CR50N – erhielten die Einstufung „Full Compatible". Dies bedeutet, dass sie ohne Einschränkungen innerhalb des gesamten PET-Recyclingprozesses
More news about: SK chemicals